Table 2.
Summary of juvenile human chondrocyte neocartilage comparing supplemented medium and adenoviral BMP-2 transduction
| Measurement | Growth condition | |||
|---|---|---|---|---|
| Naïve-DMEM | Naïve-CDM | AdBMP-2-DMEM | AdBMP-2-CDM | |
| Weight | 2.2 ± 1.3 mg | 7.9 ± 1.6 mg | 6.1 ± 0.6 mg | 8.0 ± 1.4 mg |
| Viability | 90% ± 6% | 90% ± 7% | 70% ± 12% | 76% ± 8% |
| BMP-2 production (Day 14) | 175 ± 191 pg/mL | 43 ± 38 pg/mL | 6.2 ± 6 ng/mL | 619 ± 345 ng/mL |
| Bern score total | 1.8 ± 1.5 | 8.0 ± 1.0 | 3.7 ± 1.8 | 5.2 ± 2.8 |
| Collagen type II:I ratio | 0.56 ± 0.07 | 2.4 ± 0.05 | 0.70 ± 0.42 | 2.3 ± 0.09 |
Mean ± SD; DMEM = standard medium, consisting of Dulbecco’s Modified Eagle’s Medium, 10% fetal bovine serum, 1% penicillin-streptomycin; CDM = supplemented medium, consisting of a serum-free basal medium with dexamethasone, ascorbate, insulin, transferrin, selenium, pyruvate, proline, gentamicin, amphotericin, L-glutamine, and 10 μg/ml TGF-β; Naïve = untransduced chondrocytes; AdBMP-2 = adenoviral BMP-2 transduced juvenile human articular chondrocytes.